clopidogrel has been researched along with guaifenesin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amagase, K; Hara, D; Murakami, T; Takeuchi, K; Yoshida, Y | 1 |
1 review(s) available for clopidogrel and guaifenesin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for clopidogrel and guaifenesin
| Article | Year |
|---|---|
Prophylactic effect of egualen sodium, a stable azulene derivative, on gastrointestinal damage induced by ischemia/reperfusion, double antiplatelet therapy and loxoprofen in rats.
Topics: Animals; Aspirin; Azulenes; Benzoquinones; Clopidogrel; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastrointestinal Tract; Heptanoic Acids; Male; Mice; Mice, Inbred C57BL; Mucus; Nitric Oxide Synthase Type II; Peptic Ulcer; Peroxidase; Phenylpropionates; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sesquiterpenes; Ticlopidine | 2013 |